Join

Compare · BBLG vs EW

BBLG vs EW

Side-by-side comparison of Bone Biologics Corp (BBLG) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BBLG and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
  • EW is the larger of the two at $65.47B, about 3067.3x BBLG ($21.3M).
  • EW has hit the wire 5 times in the past 4 weeks while BBLG has been quiet.
  • EW has more recent analyst coverage (25 ratings vs 0 for BBLG).
MetricBBLGEW
Company
Bone Biologics Corp
Edwards Lifesciences Corporation
Price
$1.40+0.72%
$84.16+5.54%
Market cap
$21.3M
$65.47B
1M return
-
+1.83%
1Y return
-
+11.37%
Industry
Industrial Specialties
Industrial Specialties
Exchange
NASDAQ
NYSE
IPO
News (4w)
0
5
Recent ratings
0
25
BBLG

Bone Biologics Corp

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

EW

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.